132 related articles for article (PubMed ID: 27505709)
21. High expression of B lymphocyte stimulator in lesional keratinocytes of patients with cutaneous lupus erythematosus.
Wenzel J; Landmann A; Vorwerk G; Kuhn A
Exp Dermatol; 2018 Jan; 27(1):95-97. PubMed ID: 28833566
[TBL] [Abstract][Full Text] [Related]
22. Belimumab--an anti-BLyS human monoclonal antibody for rheumatoid arthritis.
Jin X; Ding C
Expert Opin Biol Ther; 2013 Feb; 13(2):315-22. PubMed ID: 23268610
[TBL] [Abstract][Full Text] [Related]
23. In vivo BLyS/BAFF neutralization ameliorates islet-directed autoimmunity in nonobese diabetic mice.
Zekavat G; Rostami SY; Badkerhanian A; Parsons RF; Koeberlein B; Yu M; Ward CD; Migone TS; Yu L; Eisenbarth GS; Cancro MP; Naji A; Noorchashm H
J Immunol; 2008 Dec; 181(11):8133-44. PubMed ID: 19018006
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold.
Veri MC; Burke S; Huang L; Li H; Gorlatov S; Tuaillon N; Rainey GJ; Ciccarone V; Zhang T; Shah K; Jin L; Ning L; Minor T; Moore PA; Koenig S; Johnson S; Bonvini E
Arthritis Rheum; 2010 Jul; 62(7):1933-43. PubMed ID: 20506263
[TBL] [Abstract][Full Text] [Related]
25. Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation.
Goenka R; Matthews AH; Zhang B; O'Neill PJ; Scholz JL; Migone TS; Leonard WJ; Stohl W; Hershberg U; Cancro MP
J Exp Med; 2014 Jan; 211(1):45-56. PubMed ID: 24367004
[TBL] [Abstract][Full Text] [Related]
26. The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity.
Cancro MP
Ann Rheum Dis; 2006 Nov; 65 Suppl 3(Suppl 3):iii34-6. PubMed ID: 17038469
[TBL] [Abstract][Full Text] [Related]
27. An optimized B lymphocyte stimulator (BLyS) antagonist peptide inhibits the interaction of BLyS with BCMA.
Tian Y; Zhu YF; Wu Z; Feng JN; Li Y; Shen BF; Sun J
Biotechnol Lett; 2013 Apr; 35(4):523-8. PubMed ID: 23242501
[TBL] [Abstract][Full Text] [Related]
28. Amelioration of experimental autoimmune encephalomyelitis by BLyS autovaccine.
Xue X; Feng G; Li M; Qin X; Wu S; Zhang C; You Y; Wang W; Jiang C; Liu Y; Zhu W; Ran Y; Zhang Z; Yan Z; Han W; Zhang Y
Vaccine; 2008 Jun; 26(23):2873-81. PubMed ID: 18440104
[TBL] [Abstract][Full Text] [Related]
29. Anti-BlyS antibody reduces the immune reaction against enzyme and enhances the efficacy of enzyme replacement therapy in Fabry disease model mice.
Sato Y; Ida H; Ohashi T
Clin Immunol; 2017 May; 178():56-63. PubMed ID: 28161408
[TBL] [Abstract][Full Text] [Related]
30. [Research progress on B cell surface molecules targeted therapy in rheumatoid arthritis].
Di W; Chang Y; Wu YJ; Wei W
Sheng Li Ke Xue Jin Zhan; 2011 Jun; 42(3):175-80. PubMed ID: 21932514
[TBL] [Abstract][Full Text] [Related]
31. Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.
Mosak J; Furie R
Lupus; 2013 Apr; 22(4):361-71. PubMed ID: 23553779
[TBL] [Abstract][Full Text] [Related]
32. Rapid and specific targeting of 125I-labeled B lymphocyte stimulator to lymphoid tissues and B cell tumors in mice.
Riccobene TA; Miceli RC; Lincoln C; Knight Y; Meadows J; Stabin MG; Sung C
J Nucl Med; 2003 Mar; 44(3):422-33. PubMed ID: 12621010
[TBL] [Abstract][Full Text] [Related]
33. APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity.
Yu G; Boone T; Delaney J; Hawkins N; Kelley M; Ramakrishnan M; McCabe S; Qiu WR; Kornuc M; Xia XZ; Guo J; Stolina M; Boyle WJ; Sarosi I; Hsu H; Senaldi G; Theill LE
Nat Immunol; 2000 Sep; 1(3):252-6. PubMed ID: 10973284
[TBL] [Abstract][Full Text] [Related]
34. Belimumab: a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus.
Dennis GJ
Clin Pharmacol Ther; 2012 Jan; 91(1):143-9. PubMed ID: 22130121
[TBL] [Abstract][Full Text] [Related]
35. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA.
Day ES; Cachero TG; Qian F; Sun Y; Wen D; Pelletier M; Hsu YM; Whitty A
Biochemistry; 2005 Feb; 44(6):1919-31. PubMed ID: 15697217
[TBL] [Abstract][Full Text] [Related]
36. Antibodies against human BLyS and APRIL attenuate EAE development in marmoset monkeys.
Jagessar SA; Heijmans N; Oh L; Bauer J; Blezer EL; Laman JD; Migone TS; Devalaraja MN; 't Hart BA
J Neuroimmune Pharmacol; 2012 Sep; 7(3):557-70. PubMed ID: 22870852
[TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo B lymphocyte-activating properties of monoclonal anti-delta antibodies. I. Determinants of B lymphocyte-activating properties.
Goroff DK; Stall A; Mond JJ; Finkelman FD
J Immunol; 1986 Apr; 136(7):2382-92. PubMed ID: 2419432
[TBL] [Abstract][Full Text] [Related]
38. Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus.
Carter RH; Zhao H; Liu X; Pelletier M; Chatham W; Kimberly R; Zhou T
Arthritis Rheum; 2005 Dec; 52(12):3943-54. PubMed ID: 16320342
[TBL] [Abstract][Full Text] [Related]
39. Downregulation of B lymphocyte stimulator expression by curcumin in B lymphocyte via suppressing nuclear translocation of NF-κB.
Huang G; Yang Y; Xu Z; Zhou P; Gong W; Li Y; Fan J; He F
Eur J Pharmacol; 2011 Jan; 650(1):451-7. PubMed ID: 20950605
[TBL] [Abstract][Full Text] [Related]
40. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.
Cambridge G; Stohl W; Leandro MJ; Migone TS; Hilbert DM; Edwards JC
Arthritis Rheum; 2006 Mar; 54(3):723-32. PubMed ID: 16508933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
